The Changing Face of Oncology Endpoint Monitoring

December 20, 2019

This article originally appeared in Journal for Clinical Studies Volume 11, Issue 6.

Oncology trials have always relied on tumor response to gauge the efficacy of the drugs they assess. But in a world of patient-centricity and value-based reimbursement, do these "hard endpoints" offer developers - and regulators - the whole story?

 

Previous Guide
Wear it on Your Sleeve — How Sensors and Wearables Help Drive Richer Insights on Intervention Effects
Wear it on Your Sleeve — How Sensors and Wearables Help Drive Richer Insights on Intervention Effects

As previously featured in PharmaVoice, Bill Byrom shares how the use of sensors and wearables in clinical t...

Next Flipbook
Successful Oncology Trials Need Intelligent Supply Management
Successful Oncology Trials Need Intelligent Supply Management